Search: lecanemab — alzhub.org

312 results for "lecanemab".

Guides and answers on this site

Lecanemab and donanemab: benefit and riskPage

Understand · alzhub.org/treatments/lecanemab

Lecanemab and donanemab: do they work, and what are the risks? In the main trials both drugs slowed decline modestly over about 18 months in people with early Alzheimer's. Independent reviews disagree about whether that …
Alzheimer's treatments: approved drugs, trials and failuresPage

Main · alzhub.org/treatments

… genuinely debated among specialists: lecanemab and donanemab, what the trials and the independent reviews found . The trial numbers, the FDA decisions and the ARIA rates for all three approved antibodies are side by side on the …
Anti-amyloid antibodies for Alzheimer's: the trial evidencePage

Understand · alzhub.org/treatments/anti-amyloid

… 18-point CDR-SB scale with lecanemab over 18 months 0.70 points less worsening on the CDR-SB with donanemab over 76 weeks 107 extra cases of brain swelling (ARIA-E) per 1,000 people treated, across the class On this page What …
What are lecanemab (Leqembi) and donanemab (Kisunla), and who can take them?Question

Questions and answers · Treatment · alzhub.org/faq#anti-amyloid-drugs

… infusion every four weeks; lecanemab is given intravenously or, in newer formulations, by subcutaneous injection. (Leqembi prescribing information) (Kisunla prescribing information) (FDA)

Research summaries 283

Showing the best 200 of 283, 1–10, page 1 of 20. Filter these by subject, year and score in the research library →

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibodyResearch summary

Research summaries · alzhub.org/study/a-randomized-double-blind-phase-2b-proof-of-concept-clinical-trial-in-33865446

Background Lecanemab (BAN2401), an IgG1 monoclonal antibody, preferentially targets soluble aggregated amyloid beta (Aβ), with activity across oligomers, protofibrils, and insoluble fibrils. BAN2401-G000-201, a randomized …
A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databasesResearch summary

Research summaries · alzhub.org/study/a-real-world-pharmacovigilance-study-of-adverse-drug-reactions-40290431

Background Lecanemab and Aducanumab are two novel anti-amyloid beta (Aβ) therapies for Alzheimer's disease (AD) that have shown promise in slowing cognitive decline. However, their safety profiles remain unclear due to limited …
Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's diseaseResearch summary

Research summaries · alzhub.org/study/clarity-ad-asian-regional-analysis-of-a-phase-iii-trial-of-lecanemab-40189473

… Singapore:13). The efficacy of lecanemab was consistent with the overall population. For the primary endpoint, there was a slowing of decline with lecanemab in the CDR-SB at 18 months compared to placebo in the Asian region …
Comparison of safety of lecanemab and aducanumab: a real-world disproportionality analysis using the FDA adverse event reporting systemResearch summary

Research summaries · alzhub.org/study/comparison-of-safety-of-lecanemab-and-aducanumab-a-real-world-40520157

… drug events (ADEs) of lecanemab and aducanumab separately, there is a lack of comparison between these two drugs, and no exploration of gender differences. This study aims to compare the adverse reaction signals of lecanemab and …
Cost-Effectiveness of Lecanemab for Individuals With Early-Stage Alzheimer DiseaseResearch summary

Research summaries · alzhub.org/study/cost-effectiveness-of-lecanemab-for-individuals-with-early-stage-38484190

… cost-effectiveness of lecanemab (Leqembi), a monoclonal antibody approved by the US Food and Drug Administration in January 2023 for the treatment of mild cognitive impairment (MCI) or mild dementia due to Alzheimer disease (AD). …
Dynamic changes in plasma biomarkers of Alzheimer's disease in patients treated with lecanemab: a longitudinal cohort studyResearch summary

Research summaries · alzhub.org/study/dynamic-changes-in-plasma-biomarkers-of-alzheimer-s-disease-in-42785333

The study included 197 patients in whom lecanemab infusions had been started (lecanemab group), as well as 173 patients in whom lecanemab had been ordered but not yet started, who were combined with 1139 research participants …
Higher phosphorylated tau levels predict cognitive decline and amyloid-related imaging abnormalities during lecanemab treatment: clinical practice dataResearch summary

Research summaries · alzhub.org/study/higher-phosphorylated-tau-levels-predict-cognitive-decline-and-41276859

Background Lecanemab was recently approved for the treatment of patients with early Alzheimer's disease (AD) and demonstrated reduced senile amyloid plaque and less decline on the measures of cognition and function in clinical …
Krankheitsmodifizierende Therapie mit Lecanemab bei früher Alzheimer-DemenzResearch summary

Research summaries · alzhub.org/study/krankheitsmodifizierende-therapie-mit-lecanemab-bei-fruher-alzheimer-41052542

… AD zu verlangsamen. Lecanemab ist durch den Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittel-Agentur (EMA) für die Zulassung bei Patienten mit früher AD unter zwei Bedingungen empfohlen worden. Erstens sollen …
Lecanemab Binds to Transgenic Mouse Model‐Derived Amyloid‐β Fibril Structures Resembling Alzheimer's Disease Type I, Type II and Arctic FoldsResearch summary

Research summaries · alzhub.org/study/lecanemab-binds-to-transgenic-mouse-modelderived-amyloid-fibril-40495448

Our results show that lecanemab exhibits high binding affinity to amyloid-β fibril structures that have a flexible N-terminus in common, as is the case for type I, type II and murine type III amyloid-β fibril polymorphs, which …
Lecanemab QuestionsResearch summary

Research summaries · alzhub.org/study/lecanemab-questions-38484213

… controlled trial of lecanemab, reporting the efficacy of the drug in slowing the progression of early Alzheimer disease, quickly led to approval by the FDA and widespread acceptance of lecanemab treatment. However, there are a …

How this search works

There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.

One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.

27580 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-03. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.